
Hans Petter Eikesdal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9137401/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Semi-automatic segmentation from intrinsically-registered 18F-FDG–PET/MRI for treatment response assessment in a breast cancer cohort: comparison to manual DCE–MRI. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2020, 33, 317-328.	2.0	7
2	An Ultrasensitive Routine LC-MS/MS Method for Estradiol and Estrone in the Clinically Relevant Sub-Picomolar Range. Journal of the Endocrine Society, 2020, 4, bvaa047.	0.2	17
3	Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer. Acta Oncológica, 2019, 58, 385-387.	1.8	2
4	Abstract 2507: Genetic alterations affecting treatment response in locally advanced breast cancers. , 2019, , .		0
5	Divergent Activity of the Pseudogene <i>PTENP1</i> in ER-Positive and Negative Breast Cancer. Molecular Cancer Research, 2018, 16, 78-89.	3.4	34
6	BMP7 Signaling in <i>TGFBR2</i> -Deficient Stromal Cells Provokes Epithelial Carcinogenesis. Molecular Cancer Research, 2018, 16, 1568-1578.	3.4	7
7	High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function. Breast Cancer Research and Treatment, 2017, 163, 177-190.	2.5	16
8	BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. European Journal of Human Genetics, 2016, 24, 881-888.	2.8	58
9	Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy. JCI Insight, 2016, 1, e90733.	5.0	19
10	Impaired lymphatic function accelerates cancer growth. Oncotarget, 2016, 7, 45789-45802.	1.8	20
11	Abstract 3986: Introduction of PTEN pseudogene in murine breast cancer upregulates PTEN, p53 and activating protein 2 gamma and delays tumor growth. , 2015, , .		1
12	The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. Expert Opinion on Pharmacotherapy, 2014, 15, 681-700.	1.8	41
13	Abstract 3539: The noncoding PTEN pseudogene influences PI3K signaling and inhibits breast cancer progression. , 2014, , .		0
14	Tumor vasculature: the Achilles' heel of cancer?. Expert Opinion on Therapeutic Targets, 2013, 17, 7-20.	3.4	20
15	Lethal pneumonitis after docetaxel chemotherapy: Case report and review of the literature. Acta OncolÅ ³ gica, 2013, 52, 1034-1038.	1.8	10
16	Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocrine-Related Cancer, 2013, 20, R183-R201.	3.1	88
17	The Multifaceted Role of Cancer Associated Fibroblasts in Tumor Progression. , 2011, , 361-380.		1
18	Endogenous Matrix-Derived Inhibitors of Angiogenesis. Pharmaceuticals, 2010, 3, 3021-3039.	3.8	9

HANS PETTER EIKESDAL

#	Article	IF	CITATIONS
19	Drug resistance associated with antiangiogenesis therapy. Seminars in Cancer Biology, 2009, 19, 310-317.	9.6	53
20	Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 15040-15045.	7.1	69
21	The influence of combretastatin A-4 and vinblastine on interstitial fluid pressure in BT4An rat gliomas. Cancer Letters, 2002, 178, 209-217.	7.2	15
22	Tumor vasculature is targeted by the combination of combretastatin A-4 and hyperthermia. Radiotherapy and Oncology, 2001, 61, 313-320.	0.6	21
23	Vinblastine and hyperthermia target the neovasculature in BT 4 AN rat gliomas: therapeutic implications of the vascular phenotype. International Journal of Radiation Oncology Biology Physics, 2001, 51, 535-544.	0.8	20
24	The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. International Journal of Radiation Oncology Biology Physics, 2000, 46, 645-652.	0.8	32